If you need assistance with locating additional pharmacy contact information please reach out to [email protected] or contact the main office
Learning Objectives After completing this activity, nutrition professionals will better be able to: Discuss the different GLP-1 receptor agonists and understand their use as anti-obesity medications
The FDA approved oral semaglutide (Rybelsus) in 2019, and other oral GLP-1 medications like orforglipron are in development
However, many studies are funded by pharmaceutical companies, meaning there is room for potential bias and conflict of interest
Activation of GLP-1R slows gastric emptying, enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriate glucagon secretion, and produces a robust central satiety signal via vagal afferents and hypothalamic circuits
And most importantly, dont hesitate to reach out to a professional